CML is a well-characterised and understood stem cell disease, with direct targeting of the oncoprotein BCR::ABL1 with TKI making the disease manageable for the majority of patients [32, 33]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.